HC Wainwright Issues Positive Forecast for PTGX Earnings

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) – HC Wainwright upped their Q1 2025 earnings estimates for Protagonist Therapeutics in a research report issued to clients and investors on Monday, February 24th. HC Wainwright analyst D. Tsao now expects that the company will post earnings of ($0.57) per share for the quarter, up from their prior estimate of ($0.61). HC Wainwright currently has a “Buy” rating and a $54.00 target price on the stock. The consensus estimate for Protagonist Therapeutics’ current full-year earnings is $2.43 per share. HC Wainwright also issued estimates for Protagonist Therapeutics’ Q2 2025 earnings at ($0.65) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at $1.00 EPS, FY2025 earnings at ($0.62) EPS, FY2026 earnings at ($1.52) EPS, FY2027 earnings at ($0.39) EPS, FY2028 earnings at $2.83 EPS and FY2029 earnings at $6.91 EPS.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its earnings results on Friday, February 21st. The company reported $1.98 EPS for the quarter, beating the consensus estimate of ($0.09) by $2.07. The company had revenue of $170.64 million during the quarter, compared to analysts’ expectations of $56.65 million. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%.

A number of other equities analysts have also recently commented on the company. JMP Securities reissued a “market outperform” rating and set a $58.00 price target on shares of Protagonist Therapeutics in a report on Friday, February 7th. The Goldman Sachs Group lowered their target price on Protagonist Therapeutics from $43.00 to $38.00 and set a “neutral” rating for the company in a research note on Monday. StockNews.com cut shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 10th. JPMorgan Chase & Co. lifted their price target on shares of Protagonist Therapeutics from $51.00 to $53.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Finally, BMO Capital Markets began coverage on shares of Protagonist Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $62.00 price objective for the company. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Protagonist Therapeutics has an average rating of “Moderate Buy” and an average price target of $55.44.

Protagonist Therapeutics Price Performance

NASDAQ PTGX opened at $35.09 on Wednesday. The business has a fifty day moving average price of $38.14 and a two-hundred day moving average price of $41.89. The stock has a market capitalization of $2.09 billion, a PE ratio of 13.19 and a beta of 2.22. Protagonist Therapeutics has a fifty-two week low of $24.22 and a fifty-two week high of $48.89.

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 5,359 shares of the company’s stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $38.18, for a total value of $204,606.62. Following the sale, the chief executive officer now owns 540,260 shares in the company, valued at approximately $20,627,126.80. The trade was a 0.98 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Protagonist Therapeutics

Hedge funds have recently made changes to their positions in the stock. Bank of Montreal Can boosted its holdings in Protagonist Therapeutics by 4.5% in the fourth quarter. Bank of Montreal Can now owns 6,250 shares of the company’s stock valued at $241,000 after acquiring an additional 270 shares during the last quarter. Maryland State Retirement & Pension System boosted its stake in shares of Protagonist Therapeutics by 1.4% in the 4th quarter. Maryland State Retirement & Pension System now owns 20,170 shares of the company’s stock valued at $779,000 after purchasing an additional 278 shares during the last quarter. Nisa Investment Advisors LLC increased its position in shares of Protagonist Therapeutics by 10.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company’s stock worth $121,000 after buying an additional 295 shares during the period. Louisiana State Employees Retirement System raised its stake in Protagonist Therapeutics by 1.1% during the fourth quarter. Louisiana State Employees Retirement System now owns 28,800 shares of the company’s stock worth $1,112,000 after buying an additional 300 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Protagonist Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,130 shares of the company’s stock valued at $95,000 after buying an additional 379 shares during the period. 98.63% of the stock is currently owned by institutional investors.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.